NCT06304298

Brief Summary

Effect of iPACK block on NLR and PLR following knee arthroplasty

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for phase_4

Timeline
Completed

Started Mar 2024

Shorter than P25 for phase_4

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 24, 2023

Completed
10 months until next milestone

First Posted

Study publicly available on registry

March 12, 2024

Completed
18 days until next milestone

Study Start

First participant enrolled

March 30, 2024

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 16, 2025

Completed
25 days until next milestone

Study Completion

Last participant's last visit for all outcomes

February 10, 2025

Completed
Last Updated

March 24, 2025

Status Verified

March 1, 2025

Enrollment Period

10 months

First QC Date

May 24, 2023

Last Update Submit

March 20, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Neutrophil-to-lymphocyte ratio

    Neutrophil to lymphocyte ratio (NLR) is used as a marker of subclinical inflammation. It is calculated by dividing the number of neutrophils by number of lymphocytes, usually from peripheral blood sample, but sometimes also from cells that infiltrate tissue, such as tumor.

    12 hours after surgery

Secondary Outcomes (14)

  • PLR

    12 hours after surgery

  • PLR

    24 hours after surgery

  • PLR

    48 hours after surgery

  • NLR

    24 hours after surgery

  • NLR

    48 hours after surgery

  • +9 more secondary outcomes

Study Arms (2)

Sham blocks

ACTIVE COMPARATOR

iPACK block with 20ml of 0.9% sodium chloride

Drug: 0.9% Sodium Chloride Injection

iPACK block

ACTIVE COMPARATOR

iPACK block with 20ml 0f 0.2% ropivacaine

Drug: Ropivacaine 0.2% Injectable Solution

Interventions

After spinal anesthesia, the ultrasound-guided iPACK block will be performed with 20ml of 0.9% sodium chloride

Also known as: Placebo
Sham blocks

After spinal anesthesia, the ultrasound-guided iPACK block will be performed with 20ml of 0.2% ropivacine

Also known as: iPACK block
iPACK block

Eligibility Criteria

Age20 Years - 90 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients with ASA classification I-III
  • Aged 20-90 years
  • Who will be scheduled for hip arthroplasty under spinal anesthesia

You may not qualify if:

  • Patients who have a history of bleeding diathesis
  • Take anticoagulant therapy
  • History of chronic pain before surgery
  • Multiple trauma
  • patients unable to assess their pain (dementia)
  • patients operated under general anesthesia
  • patients having an infection in region of the procedure
  • patient who do not accept the procedure

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Poznan University of Medical Sciences

Poznan, Poznań, 61-701, Poland

Location

MeSH Terms

Conditions

Osteoarthritis, Knee

Interventions

Sodium ChlorideRopivacaine

Condition Hierarchy (Ancestors)

OsteoarthritisArthritisJoint DiseasesMusculoskeletal DiseasesRheumatic Diseases

Intervention Hierarchy (Ancestors)

ChloridesHydrochloric AcidChlorine CompoundsInorganic ChemicalsSodium CompoundsAnilidesAmidesOrganic ChemicalsAniline CompoundsAmines

Study Officials

  • Małgorzata Domagalska, Ph.D.

    Poznań University of Medical Sciences

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 24, 2023

First Posted

March 12, 2024

Study Start

March 30, 2024

Primary Completion

January 16, 2025

Study Completion

February 10, 2025

Last Updated

March 24, 2025

Record last verified: 2025-03

Data Sharing

IPD Sharing
Will not share

Locations